Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Heparin vs low molecular weight heparin

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Heparin vs prostaglandin E1

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).

1 finding from 1 review

Heparin vs prostaglandin E1

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).

1 finding from 1 review

Heparin vs prostaglandin E1

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).

1 finding from 1 review

Heparin vs no treatment

Incidence of hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia

It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).

1 finding from 1 review

Heparin vs no treatment

Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia

It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).

1 finding from 1 review

Heparin vs no treatment

All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia

Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).

1 finding from 1 review